Newsfiscal.ai
Unicycive Therapeutics Announces FDA Acceptance of Resubmitted NDA for Oxylanthanum Carbonate
· Published
Article summary
The FDA has accepted Unicycive Therapeutics' resubmitted New Drug Application (NDA) for oxylanthanum carbonate, setting a PDUFA target action date of March 25, 2027.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…